Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDA | P32320 | 8/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.35 |
| ▸ | UMPS | P11172 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.31 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.31 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8772894 | 0.85 | CDA (0.59) | CDA | |
| SCHEMBL31436139 | 0.81 | CDA (0.50) | CDA | |
| SCHEMBL31436140 | 0.81 | CDA (0.50) | CDA | |
| SCHEMBL11178912 | 0.80 | HPRT1 (0.53) | CDAHPRT1UMPSP2RY6P2RY2 | |
| SCHEMBL6015184 | 0.80 | CDA (0.66) | CDA | |
| SCHEMBL30241991 | 0.80 | CDA (0.66) | CDA | |
| SCHEMBL399314 | 0.80 | CDA (0.66) | CDA | |
| SCHEMBL18503564 | 0.80 | CDA (0.66) | CDA | |
| SCHEMBL18512836 | 0.80 | CDA (0.66) | CDA | |
| SCHEMBL11757296 | 0.80 | CDA (0.66) | CDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-01-02 | — | — | US | disclosed |
| US-12121531-B2 | TREM compositions and uses thereof | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2024-10-22 | — | — | US | disclosed |
| US-20230203509-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203510-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI LLC (US) | 2023-06-29 | — | — | US | disclosed |
| EP-4158031-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | Flagship Pioneering Innovations VI, LLC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4158032-A2 | TREM COMPOSITIONS AND METHODS RELATING THERETO | Flagship Pioneering Innovations VI, LLC (US) | 2023-04-05 | — | — | EP | disclosed |
| US-20230054178-A1 | TREM COMPOSITIONS AND USES THEREOF | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2023-02-23 | — | — | US | disclosed |
| WO-2021243290-A1 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021243301-A2 | TREM COMPOSITIONS AND METHODS RELATING THERETO | FLAGSHIP PIONEERING INNOVATIONS VI, LLC. (US) | 2021-12-02 | — | — | WO | disclosed |
| EP-0799313-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5672501-A | Base-modified enzymatic nucleic acid | RIBOZYME PHARMACEUTICALS, INC. (US) | 1997-09-30 | — | — | US | disclosed |
| WO-1996018736-A2 | METHOD AND REAGENT FOR TREATMENT OF ARTHRITIC CONDITIONS, INDUCTION OF GRAFT TOLERANCE AND REVERSAL OF IMMUNE RESPONSES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054178-A1 | TREM COMPOSITIONS AND USES THEREOF | TRMT1, TARBP1, TRMT1L | CDA 136/4885HPRT1 97/4885UMPS 622/4885 |
| US-12121531-B2 | TREM compositions and uses thereof | TRMT1, TARBP1, TRMT1L | CDA 136/4885HPRT1 97/4885UMPS 622/4885 |
| US-20250000890-A1 | TREM COMPOSITIONS AND USES THEREOF | TRMT1, TARBP1, TRMT1L | CDA 136/4885HPRT1 97/4885UMPS 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.